Zentalis Q3 net loss widens 8% year over year to $28.82 million
ZNTL•Zentalis Pharmaceuticals’ third-quarter 2026 net loss widened 8% year over year to $28.82 million, while operating expenses fell 8% to $31.15 million. It reported $228.89 million in cash, cash equivalents and marketable securities, with expected runway into the first half of 2028.
1. Quarterly results and cash
Zentalis Pharmaceuticals’ third-quarter 2026 net loss widened 8% year over year to $28.82 million, while total operating expenses fell 8% to $31.15 million. Cash, cash equivalents and marketable securities totaled $228.89 million as of September 30, providing expected runway into the first half of 2028.
2. DENALI study timing
Enrollment in DENALI Part 2c should finish in November 2026, with integrated topline results expected in the first half of 2027.
